Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE002715 |
ID: | TCMBANKHE002715 |
植物拉丁名: |
|
功能与主治: | 1. To clear heat and toxic materials, clear summer-heat and promote diuresis. 2. To relieve the metallic and drug poisoning. 3. External use for clearing away heat and promoting tissue regeneration. 4. To reduce the level of blood-fat./1. Diuretic. 2. Its coat exerts a bacteriostatic effect on staphylococcus. |
药用植物名: | 绿豆 |
药味: | Cool; Sweet |
经络: | Stomach; Heart |
临床特征: | 1. Diuretic. 2. Its coat exerts a bacteriostatic effect on staphylococcus. |
治疗类型: | 清热解毒药 |
TCM_ID_id: | 2550 |
SymMap_id: | 262 |
TCMSP_id: | 486 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000036 | sakuranetin | 4',5-Dihydroxy-7-methoxyflavanone; AC1LGHGY; SCHEMBL14410473; ZINC338283; ZB010901; AJ-19902; (2R)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one | C16H14O5 | 286.28 g/mol | COC1=CC(=C2C(=O)CC(OC2=C1)C3=CC=C(C=C3)O)O |
| TCMBANKIN000067 | Embelin | MFCD00016369; CS-1879; BS0074; CHEBI:4778; BDBM50078850; NCGC00017248-04; SCHEMBL148744; AKOS016010144; NCGC00025359-02; ZINC1531764; 2,5-Cyclohexadiene-1,4-dione, 2,5-dihydroxy-3-undecyl-; AIDS-009914; TNP00137; SBB005949; BRN 1885786; AC-542/20644009; Embelin, <i>Embelia ribes; NCI60_042031; NCGC00017248-12!2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione; HSCI1_000123; Embelin, Embelia ribes; C10342; AK115155; Apoptosis Activator III, Embelin; CCG-39906; NCGC00017248-06; BSPBio_003531; 2,5-Dihydroxy-3-undecyl-[1,4]benzoquinone; LS-40347; KBio2_004561; 4-08-00-02769 (Beilstein Handbook Reference); Embelin, >=98% (HPLC), powder; D05HSW; NSC 91874; DTXSID80203537; C17H26O4; MCULE-1558476181; KBio2_001993; 4CH-024635; C-52730; 550-24-3; V0365; embelin ; SR-01000597536; embelin; DivK1c_006597; SR-01000597536-1; KBio1_001541; EMBELIN; UNII-SHC6U8F5ER; SPECTRUM1504074; NCGC00017248-03; Embelic acid; SHC6U8F5ER; MolPort-000-165-323; Spectrum3_001931; KBioSS_001993; NSC-91874; 2,5-Dihydroxy-3-undecyl-p-benzoquinone; Tocris-2156; EINECS 208-979-8; MLS000563189; SpecPlus_000501; p-Benzoquinone,5-dihydroxy-3-undecyl-; AC1L1FFT; Spectrum5_000620; BIDD:ER0529; SMR000470851; NCGC00017248-07; 2,5-Cyclohexadiene-1,4-dione, 2,5-dihydroxy-3-undecyl- (9CI); XIAP inhibitor, Embelin; NCGC00025359-04; S7025; HY-17473; NCGC00025359-05; ST057212; 2,4-dione, 2,5-dihydroxy-3-undecyl-; NCGC00025359-03; HMS3268N13; NCGC00017248-08; KBio2_007129; ST24038748; NCGC00017248-05; KBioGR_002240; E1406_SIGMA; AIDS009914; Spectrum4_001760; HMS3652J16; 2,5-Dihydroxy-3-undecyl-2,5-cyclohexadiene-1,4-dione; AC1Q6BUE; HMS1922B07; HMS2271A03; 2,5-Dihydroxy-3-undecyl-1,4-benzoquinone; SR-01000597536-3; KB-225927; Emberine; Spectrum_001513; 2,5-dihydroxy-3-undecyl-1,4-benzochinon; KBio3_002783; SDCCGMLS-0066817.P001; NCGC00017248-02; NCGC00017248-10; NCGC00025359-01; CHEMBL221137; 2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione; NSC91874; NCGC00017248-01; FT-0712499; 2,5-dihydroxy-3-undecyl-cyclohexa-2,5-diene-1,4-dione; p-Benzoquinone, 2,5-dihydroxy-3-undecyl-; IRSFLDGTOHBADP-UHFFFAOYSA-N | C17H26O4 | 294.39 | CCCCCCCCCCCC1=C(C(=O)C=C(C1=O)O)O |
| TCMBANKIN000191 | 3,7,4'-trihydroxy-3'-(8''-acetoxy-7''-methyl-octyl)-5,6-dimethoxyflavone | C28H34O9 | |||
| TCMBANKIN000427 | VIV | T1539_SIGMA; NSC 82623; (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-ol; (+-)-alpha-Tocopherol; BRN 0094012; 5,7,8-Trimethyltocol; (2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL; 6-Chromanol, 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-; T3634_SIGMA; Prestwick_653; 10191-41-0; 59-02-9; Pheryl-E; 1406-18-4; SMR000471844; Ephanyl; MLS001066396; 3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-benzopyran-6-ol; nchembio730-comp13; 2,5,7,8-Tetramethyl-2-(4',8',12'-trimethyltridecyl)-6-chromanol; Vita plus E; CCRIS 5853; (+)-alpha-Tocopherol; CHEBI:18145; 25094-97-7; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, (2R*(4R*,8R*))-(+-)- (9CI); 16826-11-2; BPBio1_000362; (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-6-chromanol; Tocopherol (R,S); EINECS 215-798-8; ZINC04095858; Prestwick3_000404; LMPR02020001; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-, (2R)-; C02477; AIDS-072178; (2R*(4R*,8R*))-(1)-3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-benzopyran-6-ol; 89550_FLUKA; Vitamin E; NCGC00142625-01; ST073358; 5-17-04-00168 (Beilstein Handbook Reference); 4072-33-7; 181591-70-8; alpha-Tocopherol; NCGC00142625-04; BSPBio_000328; NCGC00142625-03; (+-)-Med-E; (R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-3,4-dihydro-2H-chromen-6-ol; EINECS 218-197-9; AIDS072178; EINECS 233-466-0; 11105-14-9 | C29H50O2 | 430.7 g/mol | CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C |
| TCMBANKIN001384 | isopenniclavine | Isopenniclavin; 9,10-Didehydro-8-hydroxy-6-methylergoline-8-methanol (8beta)-; UNII-957F5HGG0I; Ergoline-8alpha-methanol, 9,10-dihydro-8-hydroxy-6-methyl-; 478-92-2; 957F5HGG0I; Isopenniclavine; Ergoline-8-methanol, 9,10-didehydro-8-hydroxy-6-methyl-, (8beta)- | C16H18N2O2 | 270.33 g/mol | CN1CC(C=C2C1CC3=CNC4=CC=CC2=C34)(CO)O |
| TCMBANKIN001719 | lecithin | phosphatidylcholine; 1-Lignoceryl-2-eicsoic acid; 1-Lignoceryl-2-eicsoate; 1-Lignoceryl-2-eicsoatetraenoyl-sn-glycero-3-phosphocholine | C52H98NO7P | 880.3 g/mol | CCCCCCCCCCCCCCCCCCCCCCCCOCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCC=CCC=CCC=CCC=CCCCCC |
| TCMBANKIN001723 | methyl 6-o-p-cis-coumaroyl-β-d-glucopyra-noside | COC1C(C(C(C(O1)COC(=O)C=CC2=CC=C(C=C2)O)O)O)O | |||
| TCMBANKIN001761 | gibberellin A5 | gibberellin a5 | C19H22O5 | 330.38 | CC12C=CCC3(C1C(C45C3CCC(C4)(C(=C)C5)O)C(=O)O)OC2=O |
| TCMBANKIN002672 | Spantol | Phenprobamate; BRN 1959273; Gamaquil; NSC 50538; Benzenepropanol, carbamate (9CI); Carbamic acid, 3-phenylpropyl ester; MH532; Ansepron; .gamma.-Phenylpropyl carbamate; WLN: ZVO3R; NCGC00164589-01; .gamma.-Phenylpropylcarbamat; NSC64270; Phenprobamate [BAN:DCF:INN:JAN]; 3-Phenyl-1-propanol carbamate; NSC 64270; Qumamquil; Spantol (TN); Eirenal; Phenprobamate (JAN); Fenprobamato; NSC44682; 3-Phenylpropyl carbamate; Benzenepropanol carbamate; Nelaxan; Actiphan; 673-31-4; 1-Carbamoyloxy-3-phenylpropane; NSC50538; NSC 44682; NCIOpen2_000174; D01824; Palmita; Fenprobamato [INN-Spanish]; SMR000466378; gamma-Phenylpropyl carbamate; Extacol; Proformiphen; MH 532; HG 532; Actozine; carbamic acid 3-phenylpropyl ester; MLS000759511; 1-Propanol, 3-phenyl-, carbamate; MH-532; Phenoprobamate; EINECS 211-606-1; Tranquil; Istonil; gamma-Phenylpropylcarbamat [German]; Benzenepropanol, carbamate; Phenprobamatum [INN-Latin] | C10H13NO2 | 179.22 | C1=CC=C(C=C1)CCCOC(=O)N |
| TCMBANKIN002755 | vitexin_qt | 284.28 | |||
| TCMBANKIN004172 | (2S)-2-amino-3-[(2R)-2-amino-3-hydroxy-3-oxopropyl]disulfanylpropanoic acid | PDSP2_001252; (2S)-2-amino-3-[(2R)-2-amino-3-hydroxy-3-oxo-propyl]disulfanyl-propanoic acid; (2S)-2-amino-3-[(2R)-2-amino-3-hydroxy-3-keto-propyl]disulfanyl-propionic acid; PDSP1_001268 | C6H12N2O4S2 | 240.3 | C(C(C(=O)O)N)SSCC(C(=O)O)N |
| TCMBANKIN004522 | chrysoeriol 4'-o-(6''-o-acetyl)-β-d-glucopyrano-side | C24H24O12 | CC(=O)OCC1C(C(C(C(O1)OC2=C(C=C(C=C2)C3=CC(=O)C4=C(C=C(C=C4O3)O)O)OC)O)O)O | ||
| TCMBANKIN004707 | phosphatidic acid | C35H69O8P | 648.9 g/mol | CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)O)OC(=O)CCCCCCCCCCCCCCC | |
| TCMBANKIN006201 | elymoclavine | C16H18N2O | 254.33 | CN1CC(=CC2C1CC3=CNC4=CC=CC2=C34)CO | |
| TCMBANKIN006987 | Gulutamine | 25513-46-6; G1251_SIGMA; Glutamic acid, L-, peptides; Acidum glutamicum; BPBio1_001132; L-Glutamic acid (9CI); AIDS071819; nchembio.2007.55-comp22; (S)-2-aminopentanedioic acid; L-Glutaminic acid; 26717-13-5; E 620; Biomol-NT_000170; Lopac0_000529; D00007; L-Glutamic acid, homopolymer (9CI); Poly(alpha-L-glutamic acid); NCGC00024502-01; (2S)-2-aminoglutaric acid; NCGC00024502-03; 24938-00-9; PDSP1_001539; L-Glutamic acid (JAN); W328502_ALDRICH; alpha-L-Glutamic acid polymer; HSCI1_000269; 09581_FLUKA; AIDS-071819; G5667_SIGMA; L-Glutaminsaeure; 49449_FLUKA; nchembio816-comp2; PDSP2_000127; Glutamic acid polymer; PDSP2_001523; alpha-Glutamic acid; G8415_SIGMA; C00025; 84960-48-5; Tocris-0218; CHEBI:16015; L-alpha-Aminoglutaric acid; PDSP1_000128; Glutamic acid, L- (7CI,8CI); (2S)-2-aminopentanedioic acid; POLYGLUTAMIC ACID; LS-2330; Gulutamine (USP) | C5H9NO4 | 147.13 g/mol | C(CC(=O)O)C(C(=O)O)N |
| TCMBANKIN007245 | gibberellin A20 | CHEBI:58526; 7alpha-hydroxy-1beta-methyl-8-methylidene-13-oxo-4a,1alpha-epoxymethano-4aalpha,4bbeta-gibbane-10beta-carboxylate; gibberellin a20; (1R,2R,5S,8S,9S,10R,11R)-5-hydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.1(5,8).0(1,10).0(2,8)]heptadecane-9-carboxylate; gibberellin a 20; gibberellin A20(1-) | C19H24O5 | 332.39 | CC12CCCC3(C1C(C45C3CCC(C4)(C(=C)C5)O)C(=O)[O-])OC2=O |
| TCMBANKIN007380 | Sainfuran | CHEBI:8998; CTK5G8291; AC1L4G18; 5-Benzofuranol, 2-(2-hydroxy-4-methoxyphenyl)-6-methoxy-; 2-(2-hydroxy-4-methoxyphenyl)-6-methoxy-5-benzofuranol; 2-(2-hydroxy-4-methoxy-phenyl)-6-methoxy-1-benzofuran-5-ol; 2-(2-hydroxy-4-methoxyphenyl)-6-methoxy-1-benzofuran-5-ol; LMPK12160040; sainfuran; 90664-32-7; C08974; 2-(2-hydroxy-4-methoxy-phenyl)-6-methoxy-benzofuran-5-ol | C16H14O5 | 286.28 | COC1=CC(=C(C=C1)C2=CC3=CC(=C(C=C3O2)OC)O)O |
| TCMBANKIN008882 | phosphatidyl ethanolamine | phosphatidylethanolamine | 716.11 | CCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[NH3+])OC(=O)CCCCCCCCCCC | |
| TCMBANKIN009017 | Threonin | 89179_FLUKA; 48: PN: WO2004076659 FIGURE: 7 claimed sequence; D00041; 13095-55-1; Threonine, L- (8CI); 7013-32-3; L-Threonin; (2S)-threonine; CHEBI:16857; Threonine (VAN); Treonina [Spanish]; THREONINE (L); Threoninum [Latin]; T8625_SIAL; Butanoic acid, 2-amino-3-hydroxy-, (R-(R*,S*))-; 36676-50-3; Threonine (USP); (2S,3R)-2-Amino-3-hydroxybutyric acid; Threonine, labeled with carbon-14, L-; C00188; L-(U-14C)Threonine; L-Threonine (JP15); 2-Amino-3-hydroxybutanoic acid, (R-(R*,S*))-; NSC 16589; T8441_SIGMA; (S)-Threonine; Threonine [USAN:INN]; L-Threonine (9CI); EINECS 200-774-1; threonin; L-alpha-amino-beta-hydroxybutyric acid; (2S,3R)-2-amino-3-hydroxybutanoic acid; [R-(R*,S*)]-2-Amino-3-hydroxybutanoic acid; NSC 46701; (2S,3R)-2-amino-3-hydroxy-butanoic acid; T4071_SIAL; (2S,3R)-2-amino-3-hydroxy-butyric acid | C4H9NO3 | 119.12 g/mol | CC(C(C(=O)O)N)O |
| TCMBANKIN011129 | Z-Leu-OH | Benzyloxycarbonylleucine; Benzyloxycarbonyl-L-leucine; CHEBI:28282; 521221_ALDRICH; Z-L-Leucine; (2S)-2-(benzyloxycarbonylamino)-4-methyl-valeric acid; NSC 60039; C04335; N-Carbobenzyloxy-L-leucine; Carbobenzoxyleucine; N-((Phenylmethoxy)carbonyl)-L-leucine; N(alpha)-Benzyloxycarbonyl-L-leucine; 3-06-00-01503 (Beilstein Handbook Reference); ST5307194; N-Cbz-L-leucine; L-Leucine, N-((phenylmethoxy)carbonyl)- (9CI); (2S)-4-methyl-2-[[oxo-(phenylmethoxy)methyl]amino]pentanoic acid; N-Carbobenzoxy-L-leucine; Carbobenzoxy-L-leucine; (2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoic acid; L-N-Carboxyleucine N-benzyl ester; BRN 1253861; Leucine, N-carboxy-, N-benzyl ester, L-; N-Benzyloxycarbonyl-L-leucine; Carbobenzyloxy-L-leucine; N-Benzyloxycarbonylleucine; EINECS 217-960-3 | C6H13NO2 | 131.17 | CC(C)CC(C(=O)O)NC(=O)OCC1=CC=CC=C1 |
| TCMBANKIN011176 | pentanicacid | pentanic acid | |||
| TCMBANKIN011634 | D-Serin | EINECS 206-229-4; NSC 77689; InChI=1/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7; NCGC00094363-04; AI3-18476; (2R)-2-amino-3-hydroxypropanoic acid; EU-0101088; 84970_FLUKA; (R)-2-Amino-3-hydroxypropionic acid; BPBio1_001226; NCGC00094363-03; DL-Serine; AIDS071644; S4250_SIGMA; AIDS-071644; C00740; (R)-2-amino-3-hydroxypropanoic acid; SERINE (L); Biomol-NT_000197; Lopac0_001088; CHEBI:16523; Serine D-form | C3H7NO3 | 105.09 | C(C(C(=O)O)N)O |
| TCMBANKIN012668 | sn-Gro-1-P | L-(glycerol 3-phosphate); [(2R)-2,3-dihydroxypropyl] dihydrogen phosphate; D-(glycerol 1-phosphate); sn-Glycerol 3-phosphate; CHEBI:15978; C00093; NCGC00166329-01; (2R)-2,3-dihydroxypropyl dihydrogen phosphate; Glycerophosphoric acid; sn-glycerol 3-(dihydrogen phosphate) | C3H9O6P | 172.07 g/mol | C(C(COP(=O)(O)O)O)O |
| TCMBANKIN013972 | methyl 6-o-p-trans-coumaroyl-β-d-glucopyra-noside | ||||
| TCMBANKIN015594 | phosphatidylinositol | 1-Phosphatidyl-D-myo-inositol; Phosphatidylinositol; Phosphatidyl-1D-myo-inositol; 1-Phosphatidyl-1D-myo-inositol; Phosphatidylinositols, soya; 1-Phosphatidyl-myo-inositol; (3-Phosphatidyl)-1-D-inositol | C11H19O13P | 390.23 g/mol | C(C(COP(=O)(O)OC1C(C(C(C(C1O)O)O)O)O)OC=O)OC=O |
| TCMBANKIN017178 | Boc-D-Trp-OH | (2R)-2-[(tert-butoxy-oxomethyl)amino]-3-(1H-indol-3-yl)propanoic acid; ST5307211; 15185_FLUKA; EINECS 226-042-1; Nalpha-Boc-D-tryptophan; N-((tert-Butoxy)carbonyl)-D-tryptophan; (2R)-3-(1H-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid; (2R)-2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)propanoic acid; (2R)-2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)propionic acid | C16H20N2O4 | 304.34 | CC(C)(C)OC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)O |
| TCMBANKIN017993 | vitamin c | D01CWN; Cell C; Ronotec 100; P 1110; Suncoat VC 40; D-threo-hex-2-enoic acid gamma-lactone; Citrovit; 2-o-(beta-d-glucopyranosyl)-ascorbic acid_qt; Juvamine; SCHEMBL13468284; Vasc; CHEBI:51384; D-Lyxoascorbic acid; CHEMBL1253320; AK481251; Chewcee; D-xyloascorbic acid; C8DQ5M1Y1E; MLS001066386; AK322241; Ascorbic acid, D-; AC1LD8K5; E 300; Scorbu C; 10504-35-5; Ascorbicacid; l(+)-ascorbic acid; ZINC100006137; L-ascorbate (vitamin C); (5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; (+)-Ascorbic acid; UNII-C8DQ5M1Y1E; Ascorbinsaure; Ceklin; VC 97; (2S)-2-[(1R)-1,2-bis(oxidanyl)ethyl]-4,5-bis(oxidanyl)furan-3-one; Vicin; L-ascorbate acid; L-ascorbic acid; L-dehydroascorbic acid; ascorbate; D-threo-hex-2-enono-1,4-lactone; Kangbingfeng; D-Ascorbic acid; Viscorin 100M; ZINC100028197; (2S)-2-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxy-3-furanone; L-Ascorbic acid (8CI,9CI); Proscorbin Redoxon Ribena Ronotec 100; Hex-2-enonic acid gamma-lactone, L-threo; (5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxy-2,5-dihydrofuran-2-one; Ascorbic acid; DL-Ascorbic acid; AKOS000278050; Cebion, gamma-lactone; F91F7DA3-A3D5-4FB4-A6E7-C497C48D192A; GTPL4651; SMR000471843; Xyloascorbic acid, L-; Rontex 100; Rovimix C; (2S)-2-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; A828310 | C6H8O6 | 176.12 | C(C(C1C(=C(C(=O)O1)O)O)O)O |
| TCMBANKIN018168 | Nimbolidin B | nimbolidin b | C38H50O12 | 698.8 g/mol | CC=C(C)C(=O)OC1C2C3C(CO2)(C(CC(C3(C(C1(C)C4=C(C(CC4OC(=O)C)C5=COC=C5)C)CC(=O)OC)C)OC(=O)C)OC(=O)C)C |
| TCMBANKIN018217 | 1,2-Distearoyl-L-phosphatidic acid | 2SP; (1S)-2-(PHOSPHONOOXY)-1-[(STEAROYLOXY)METHYL]ETHYL STEARATE; stearic acid [(1R)-1-(phosphonooxymethyl)-2-stearoyloxy-ethyl] ester; [(2R)-1-octadecanoyloxy-3-phosphonooxypropan-2-yl] octadecanoate; LMGP10010028; [(1R)-1-(octadecanoyloxymethyl)-2-phosphonooxy-ethyl] octadecanoate; octadecanoic acid [(1R)-1-(1-oxooctadecoxymethyl)-2-phosphonooxyethyl] ester; Octadecanoic acid, 1-[(phosphonooxy)methyl]-1,2-ethanediyl ester, (R)-; [(2R)-1-octadecanoyloxy-3-phosphonooxy-propan-2-yl] octadecanoate; beta,gamma-Distearoyl-L-alpha-phosphatidic acid; PA(18:0/18:0) | C39H77O8P | 705 g/mol | CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)O)OC(=O)CCCCCCCCCCCCCCCCC |
| TCMBANKIN018664 | CHANOCLAVINE | SAHHMCVYMGARBT-UXBLZVDNSA-N; 2-Propen-1-ol, 2-methyl-3-[1,3,4,5-tetrahydro-4-(methylamino)benz[cd]indol-5-yl]-, [4R-[4.alpha.,5.beta.(E)]]-; 1349-51-5; chanoclavine; Chanoclavine-I; C09131; 2-Propen-1-ol, 2-methyl-3-(1,3,4,5-tetrahydro-4-(methylamino)benz(cd)indol-5-yl)-, (4R-(4alpha,5beta(E)))-; SCHEMBL10822246; 2-Methyl-3-[4-(methylamino)-1,3,4,5-tetrahydrobenzo[cd]indol-5-yl]-2-propen-1-ol-, (4R-(4alpha,5beta (E)))-; 2390-99-0; Chanoclavine I; 6,7-Secoergoline-8-methanol, 8,9-didehydro-6-methyl-, (E)-; Secaclavine; Isochanoclavin; 11012-16-1; Secaclavin; 2-Propen-1-ol, 2-methyl-3-[1,3,4,5-tetrahydro-4.beta.-(methylamino)benz[cd]indol-5.alpha.-yl]-; Chanoclavin-I; Benz[cd]indole, 2-propen-1-ol deriv.; 479-04-9 | C16H20N2O | 256.34 | CC(=CC1C(CC2=CNC3=CC=CC1=C23)[NH2+]C)CO |
| TCMBANKIN019561 | nilicacid | nilic acid | C5H10O3 | 118.13 g/mol | CC(C(C)O)C(=O)O |
| TCMBANKIN019802 | LYSERGOL | SMR000386913; lysergol; BSPBio_000528; SMP1_000185; Prestwick1_000454; NINDS_000515; MEGxp0_001732; KBio1_000515; ACon1_000057; DivK1c_000515; 1413-67-8; NCGC00016520-01; MLS001049075; CAS-602-85-7; ACon0_000797; CHEMBL1331189; IDI1_000515; (5alpha)-9,10-Didehydro-6-methylergoline-8beta-methanol; SPBio_002467; AIDS-196437; (7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinolin-9-yl)-methanol; NCGC00017367-01; Phytochem 12: 2435 (1973); Prestwick0_000454; TNP00316; ZINC3873179; AIDS196437; Prestwick_308; Prestwick2_000454; Prestwick3_000454; BPBio1_000582 | C16H18N2O | 254.33 | CN1CC(C=C2C1CC3=CNC4=CC=CC2=C34)CO |
| TCMBANKIN019942 | vitamin e | vitamin-e; LS-187838; alpha-tocopherol; tocopherol; β-Tocopherol; α-tocopher | C29H50O2 | 430.7 g/mol | CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C |
| TCMBANKIN025687 | Thiamine | (Riboflavin); thiamine; thiamine chloride; vitamin b1 | C12H18Cl2N4OS | 337.3 g/mol | [H+].CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO.[Cl-].[Cl-] |
| TCMBANKIN026017 | h-Met-h | L-2-Amino-4methylthiobutyric acid; (2S)-2-amino-4-(methylthio)butanoic acid; NSC 22946; Methionine (USP); L-Methionine Z (TN); 2-Amino-4-methylthiobutanoic acid (S)-; L-Methionine-35S; Metionina [DCIT]; 24425-78-3; h-Met-oh; M9625_SIAL; (S)-methionine; nchembio816-comp7; Acimethin; (35S)Methionine; S-Methyl-L-homocysteine; Toxin WAR (Bacillus thuringiensis strain PS205C); Soft tissue sarcoma-associated protein (human clone WO2004048938-SEQID-1139); M8439_SIAL; (L)-Methionine; (2S)-2-amino-4-(methylthio)butyric acid; 3654-96-4; 64319_FLUKA; L-Methionine Z; 58576-49-1; EINECS 200-562-9; NCGC00160620-01; (S)-(+)-Methionine; (2S)-2-amino-4-methylsulfanylbutanoic acid; C00073; C-11 Met; Poly-L-methionine; Polymethionine; L-Homocysteine, S-methyl-; HSDB 4317; L-alpha-Amino-gamma-methylmercaptobutyric acid; D00019; CCRIS 5536; L-gamma-Methylthio-alpha-aminobutyric acid; L-Methionine, labeled with carbon-11; (S)-2-amino-4-(methylthio)butyric acid; NSC 118113; nchembio.2007.56-comp4; gamma-Methylthio-alpha-aminobutyric acid; Methionine [USAN:INN]; L-Methioninum; carbon-11 methionine; (S)-2-Amino-4-(methylmercapto)butyric acid; CCRIS 5528; 26062-47-5; C-11 Methionine; Methionine (VAN); (2S)-2-amino-4-methylsulfanyl-butanoic acid; (2S)-2-amino-4-(methylsulfanyl)butanoic acid; (S)-2-Amino-4-(methylthio)butanoic acid; Methionine C 11; 2-Amino-4-(methylthio)butyric acid, (S)-; Liquimeth; Methioninum [INN-Latin]; L-2-Amino-4-(methylthio)butanoic acid; Methionine, L- (8CI); L(-)-Amino-gamma-methylthiobutyric acid; L-Methionin; InChI=1/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8; CHEBI:16643; M5308_SIGMA; L-Methionine, homopolymer; L-Methionine (JP15); L-alpha-Amino-gamma-methylthiobutyric acid | C5H11NO2S | 149.21 g/mol | CSCCC(C(=O)O)N |
| TCMBANKIN026880 | Boc-D-Tyr-OH | (2R)-2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid; ST5307213; (2R)-2-[(tert-butoxy-oxomethyl)amino]-3-(4-hydroxyphenyl)propanoic acid; 15187_FLUKA; Boc-D-tyrosine; (2R)-2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propionic acid; (2R)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid | C9H11NO3 | 181.19 | CC(C)(C)OC(=O)NC(CC1=CC=C(C=C1)O)C(=O)O |
| TCMBANKIN027150 | BDF | Fructose, pyranose form; (2R,3S,4R,5R)-2-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol; CHEBI:41005; Frutabs; 7660-25-5; (2R,3S,4R,5R)-2-(hydroxymethyl)oxane-2,3,4,5-tetrol; ZINC03861095; Fructopyranose, beta-D-; beta-D-Fructopyranose; HSDB 526; BRN 1423189; 4-01-00-04402 (Beilstein Handbook Reference); (2R,3S,4R,5R)-2-methyloltetrahydropyran-2,3,4,5-tetrol | C6H12O6 | 180.16 | C1C(C(C(C(O1)(CO)O)O)O)O |
| TCMBANKIN027689 | pharbitin | ||||
| TCMBANKIN027974 | L-Lysin | AI3-26523; h-Lys-oh; 3H-Lysine; EINECS 200-294-2; Lysine, L-; 20166-34-1; 48050-57-3; 2,6-Diaminohexanoic acid, (S)-; Hydrolysine; Lysine homopolymer, L-; Lysinum [Latin]; (S)-2,6-Diaminocaproic acid; Gidrolizin; L-Lysine, homopolymer; 280114-50-3; D02304; L5501_SIGMA; 12798-06-0; nchembio861-comp2; LYS (IUPAC abbreviation); Polylysine; 4-04-00-02717 (Beilstein Handbook Reference); (2S)-2,6-diaminohexanoic acid; L-Lysine, labeled with tritium; (S)-Lysine; (S)-alpha,epsilon-Diaminocaproic acid; L-103; L-Norleucine, 6-amino-; W384704_ALDRICH; Lisina [Spanish]; Aminutrin; alpha-Lysine; (2S)-2,6-Diamino-hexanoic acid; (S)-2,6-diaminohexanoic acid; 25104-18-1; CHEBI:18019; L9037_SIGMA; Hexanoic acid, 2,6-diamino-, (S)-; Hydrolysin; 62840_FLUKA; C00047; BRN 1722531; 6899-06-5; HSDB 2108; Lysine [USAN:INN]; Lysine (USAN); 26714-32-9 | C6H12N2O | 128.17 g/mol | C(CCN)C[CH+]C(=O)[NH-] |
| TCMBANKIN030243 | pharbiticacid c | pharbitic acid c | C44H78O26 | 1023.1 g/mol | CCCC(CCCCCCCC(CC(=O)O)O)OC1C(C(C(C(O1)COC2C(C(C(C(O2)C)O)O)O)O)O)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)C)OC5C(C(C(C(O5)C)O)O)O)O)O |
| TCMBANKIN031597 | Gibberellin A8 | 2beta,3beta,7alpha-trihydroxy-1beta-methyl-8-methylidene-13-oxo-4a,1alpha-epoxymethano-4aalpha,4bbeta-gibbane-10beta-carboxylate; gibberellin a8; (1R,2R,5S,8S,9S,10R,11S,12R,13S)-5,12,13-trihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.1(5,8).0(1,10).0(2,8)]heptadecane-9-carboxylate; CHEBI:58594; gibberellin A8(1-) | C19H24O7 | 364.39 | CC12C3C(C45CC(=C)C(C4)(CCC5C3(CC(C1O)O)OC2=O)O)C(=O)[O-] |
| TCMBANKIN031904 | Pharbitic acid D | pharbitic acid d; pharbiticacid d | C50H88O30 | 1169.2 g/mol | CCCC(CCCCCCCC(CC(=O)O)O)OC1C(C(C(C(O1)COC2C(C(C(C(O2)C)O)O)O)O)O)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)C)OC5C(C(C(C(O5)C)O)OC6C(C(C(C(O6)C)O)O)O)O)O)O |
| TCMBANKIN033920 | phosphatidylcholine | phosphatidyl choline | 314.29 | CCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCC | |
| TCMBANKIN034891 | GLO | Glucose (C-14); maltodextrin; 815-92-9; (C13)D-Glucose; D-(U-14C)Glucose; Glucose (C-13); aldehydo-D-gluco-hexose; CHEBI:42758; EINECS 224-118-9; (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal; D-GLUCOSE IN LINEAR FORM; ZINC02043211; 28823-03-2; 9050-36-6; D-Glucose, labeled with carbon-14; aldehydo-D-glucose; D-Glucose, labeled with carbon-13; (U-14C)Glucose; D-Glucose, labeled with tritium; (14C)-Glucose; 19030-38-7; (14C)D-Glucose | C6H12O6 | 192.11 g/mol | C(C(C(C(C(C=O)O)O)O)O)O |
| TCMBANKIN036837 | vitexin | 49513_FLUKA; vitexin ; vitexin-7-olate anion; Flavone, 8-D-glucosyl-4',5,7-trihydroxy-; 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]chromone; vitexin-7-olate; vitex-in; 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; 8-beta-D-Glucopyranosyl-apigenin; 521-33-5; CHEBI:16954; 8-beta-D-Glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Vitexin; vitexin-7-olate(1-); 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]-4-chromenone; Apigenin 8-C-glucoside; 8C-hexosyl apigenin; (1S)-1,5-anhydro-1-[5-hydroxy-2-(4-hydroxyphenyl)-7-oxido-4-oxo-4H-chromen-8-yl]-D-glucitol; CHEBI:57963; (1S)-1,5-anhydro-1-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-8-yl]-D-glucitol; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-beta-D-glucopyranosyl-2-(4-hydroxyphenyl)-; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-.beta.-D- glucopyranosyl-2-(4-hydroxyphenyl)-; 8-C-beta-glucopyranosylapigenin; 4H-1-Benzopyran-4-one, 8-beta-D-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-; NCGC00163642-01; C01460; EINECS 222-963-8; 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; vitexin anion; 3681-93-4; AIDS026705; AIDS-026705 | C21H20O10 | 432.378 | c1([H])c(C2=C([H])C(c3c(c([C@]4([H])O[C@]([H])(C([H])([H])O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]4([H])O[H])c(O[H])c([H])c3O[H])O2)=O)c([H])c([H])c(O[H])c1[H] |
| TCMBANKIN038308 | isoliquiritin | MolPort-001-742-630; 7014-39-3; 5041-81-6; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-(beta-D-glucopyranosyloxy)phenyl)-, (2E)-; C16978; Q-100563; BDBM50362885; (E)-1-(2,4-dihydroxyphenyl)-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxyphenyl]prop-2-en-1-one; SCHEMBL676338; 4-beta-D-glucopyranosyloxy-2',4'-dihydroxy-trans-chalcone; I07-0258; Isoliquiritin; X1193; 2Y348H1V4W; MEGxp0_001945; YNWXJFQOCHMPCK-LXGDFETPSA-N; CHEMBL599763; UNII-2Y348H1V4W; AKOS015897131; X1167; AC1NSX26; BG01706425; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-[4-(.beta.-D-glucopyranosyloxy)phenyl]-, (2E)-; AK554321; AT-28971; 4-[(1E)-3-(2,4-dihydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl beta-D-glucopyranoside; N1750; (E)-1-(2,4-dihydroxyphenyl)-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-en-1-one; MFCD00272145; ZINC33832004; LMPK12120021; 4-(beta-D-Glucopyranosyloxy)-2',4'-dihydroxychalcone; AK544982; CHEBI:80839; Neoisoliquritin | C21H22O9 | 418.394 | c1([H])c(O[H])c(C(=O)\C([H])=C([H])\c2c([H])c([H])c(O[C@]3([H])O[C@]([H])(C([H])([H])O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]3([H])O[H])c([H])c2[H])c([H])c([H])c1O[H] |
| TCMBANKIN038311 | Manghaslin | manghaslin; LMPK12112115 | 756.66 | ||
| TCMBANKIN043230 | myricetin-3-rutinoside | C27H30O17 | 626.5 g/mol | CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C(=C5)O)O)O)O)O)O)O)O)O | |
| TCMBANKIN043730 | alpha-vetivone | SCHEMBL1545445; alpha-Vetivone; 2(3H)-Naphthalenone, 4,4a,5,6,7,8-hexahydro-4,4a-dimethyl-6-(1-methylethylidene)-, (4R,4aS)-; EINECS 239-855-1; UNII-WA62V77MMV; CHEBI:10339; (4R,4aS)-4,4a-dimethyl-6-propan-2-ylidene-4,5,7,8-tetrahydro-3H-naphthalen-2-one; WA62V77MMV; 6152-50-7; AC1L9CR8; α-vetivone; Isonootkatone; (4R,4aS)-6-isopropylidene-4,4a-dimethyl-4,5,7,8-tetrahydro-3H-naphthalen-2-one; C09744; Isonootkaton; 15764-04-2; 89-89-4; (4R-cis)-4,4a,5,6,7,8-Hexahydro-4,4a-dimethyl-6-(1-methylethylidene)naphthalen-2(3H)-one | C15H22O | 218.33 g/mol | CC1CC(=O)C=C2C1(CC(=C(C)C)CC2)C |
| TCMBANKIN043914 | Clitorin | CHEMBL1454324; Clitorin; MLS000563044; HMS2268K14; SMR001215819 | 740.66 | ||
| TCMBANKIN044511 | chrysoeriol 4'-o-β-d-glucopyranoside | C22H22O11 | COC1=C(C=CC(=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O | ||
| TCMBANKIN057923 | glycin | Tocris-0219; G5417_SIGMA; WLN: Z1VQ; LS-218; 56-40-6; Glycosthene; G7126_SIGMA; Hgly; Glycine-UL-14C hydrochloride; EINECS 200-272-2; Padil; Polyglycine II; AB-131/40217813; Acido aminoacetico [INN-Spanish]; Glycine [INN]; G7403_SIGMA; CCRIS 5915; GLY (IUPAC abbrev); W328707_ALDRICH; Glycine-2-3H; G3649_SIGMA; InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5; Glycine iron sulphate (1:1); NSC 25936; P8791_SIGMA; Leimzucker; Gyn-Hydralin; D00011; Aminoessigsaeure; 50046_FLUKA; Acidum aminoaceticum [INN-Latin]; Aminoethanoic acid; aminoacetic acid; AI3-04085; 33242-26-1; H2N-CH2-COOH; C00037; G8898_SIGMA; Glyzin; G0398_SIGMA; Amitone; Hampshire glycine; Glycocoll; G5523_SIGMA; Acide aminoacetique [INN-French]; Glycine-carboxy-14C hydrochloride; Glicina [INN-Spanish]; Glycinum [INN-Latin]; Glykokoll; ST5213923; 15527_RIEDEL; 7490-95-1; NChemBio.2007.13-comp1; Glycine, non-medical; BPBio1_001222; Biomol-NT_000195; 57678-19-0; Glycolixir; 63183-41-5; 87867-94-5; HSDB 495; AIDS071643; FEMA No. 3287; CHEBI:15428; 33226_RIEDEL; Sucre de gelatine; 17829-66-2; 410225_SIAL; NCGC00024503-01; 2-Aminoacetic acid; Aminoazijnzuur; NSC25936; Glycine (JP15/USP); polyglycine; 52955-63-2; carbonocyanidic acid; 32817-15-5; 2-aminoethanoic acid; Aciport; L-Glycine; Glicoamin; 25718-94-9; Acetic acid, amino-; G8790_SIGMA; AIDS-071643; NCGC00024503-02; Glycine, homopolymer (VAN); glycine;CHEMBL451140; N'-[N-(2a,3b-Dihydroxy-12-oleanen-28-oyl)-L-alanyl]-glycine; 2-[[(2S)-2-[[(4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]amino]propanoyl]amino]acetic acid;GLY | C2H5NO2 | 75.07 g/mol | C(C(=O)O)N |
| TCMBANKIN057965 | arginine | L(+ )-arginine;EINECS 230-571-3; (2S)-2-amino-5-guanidino-pentanoic acid; EINECS 200-811-1; (S)-2-Amino-5-guanidinovaleric acid; DL-Arginine; (L)-Arginine; Arginine hydrochloride(USAN); 1-Amino-4-guanidovaleric acid; L-Ornithine, N5-(aminoiminomethyl)-; W381918_ALDRICH; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid; Arginine [USAN:INN]; S-(+)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; L-Arginine, labeled with tritium; AI3-24165; AIDS-121865; (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; NSC203450 (HYDROCHLORIDE); A5006_SIAL; (+-)-Arginine; L-Norvaline, 5-((aminoiminomethyl)amino)-; AIDS121865; Lopac0_000077; Tocris-0663; Arginine (VAN); 4455-52-1; CCRIS 3609; BRN 1725413; NCGC00015064-01; (2S)-2-amino-5-(carbamimidamido)pentanoic acid; (2S)-2-amino-5-guanidinopentanoic acid; D02982; Argininum [INN-Latin]; C00062; 7200-25-1; A8094_SIGMA; 11009_FLUKA; Poly(L-arginine); (2S)-2-amino-5-guanidino-valeric acid; Lopac-A-5006; NSC 206269; HSDB 1429; CHEBI:16467; L-Arginine, homopolymer; L-Arginine (9CI); Arginina [INN-Spanish]; 4-04-00-02648 (Beilstein Handbook Reference); (S)-2-amino-5-guanidinopentanoic acid; (S)-2-Amino-5-((aminoiminomethyl)amino)pentanoic acid; Arginine, L- (8CI); L-Arginine (JP15); EU-0100077; L-alpha-Amino-delta-guanidinovaleric acid; NSC7914 (HYDROCHLORIDE); Arginine (USP); 1119-34-2 (HYDROCHLORIDE); Pentanoic acid, 2-amino-5-((aminoiminomethyl)amino)-, (S)-; L-Arg; L-Norvaline, 5-[(aminoiminomethyl)amino]-; 142-49-4; A4474_SIAL; InChI=1/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s; L-Arginin; Arginine, DL-; NCGC00024715-01;AC1ODX8E; [(4S)-5-amino-4-azaniumyl-5-oxopentyl]-(diaminomethylidene)azanium; [AMINO({[(4S)-4-AMMONIO-4-CARBAMOYLBUTYL]AMINO})METHYLIDENE]AZANIUM | C6H14N4O2 | 174.2 g/mol | C(CC(C(=O)O)N)CN=C(N)N |
| TCMBANKIN058060 | gallic acid | Spectrum4_001544; NSC-755825; 4CN-0954; KBio2_000822; NCGC00260064-01; KBio3_001168; CHEBI:30778; GTPL5549; D0Y3TZ; NCGC00091125-01; 632XD903SP; ARONIS23903; Spectrum5_000108; Jsp002851; T7419; Gallic acid, puriss., 98.0%; I14-9302; NCGC00091125-07; ZINC1504; 3,4,5-trihydroxybenzoic acid (ACD/Name 4.0); KBioGR_002008; AK-65266; pyrogallol-5-carboxylate; BRD-K77345217-001-01-9; Gallicum acidum; LNTHITQWFMADLM-UHFFFAOYSA-N; KBio2_003390; EBD679760; NCGC00091125-04; AJ-08037; Gallic acid; ZB000350; BG01502846; A808977; (?)-Gallic acid; WLN: QVR CQ DQ EQ; N1830; AC1NEVA5; SBB008781; 149-91-7; GALLIC ACID ANHYDROUS; Gallic acid [NF]; KS-00000IWM; CS-8191; LS-870; C01424; KS-00004784; CHEBI:16918; SPECTRUM210369; c0006; UNII-632XD903SP; ACMC-20aku5; CTK0H5618; BIDD:ER0374; AC1Q732X; NCGC00091125-02; F1908-0156; Oprea1_087792; CG0029; DSSTox_RID_75711; Kyselina 3,4,5-trihydroxybenzoova; 3-10-00-02070 (Beilstein Handbook Reference); RP23206; NSC36997; Gallic acid, certified reference material, TraceCERT(R); AI3-16412; CCG-38670; STK298718; Tox21_202515; bmse000389; AN-15162; AB00052697_03; SR-05000001537-2; NSC-36997; 1886-EP2374526A1; 5-Carboxybenzene-1,2,3-triol; KBio2_005958; SR-05000001537-3; NCGC00091125-05; KBio1_001347; Kyselina gallova [Czech]; KSC175M1R; KBioSS_000822; HMS2091A07; gallate; CPD-183; Spectrum3_000254; 78563C7D-0E2D-4766-A8EA-670A03C78FCF; gallic acid ; InChI=1/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12; GDE; SBI-0052184.P002; EINECS 205-749-9; CAS-149-91-7; Kyselina gallova; J3.617.291F; Benzoic acid, 3,4,5-trihydroxy-; BG00601456; DivK1c_006403; Benzoic acid,4,5-trihydroxy-; gallic acid for microelectronic industrial; BRN 2050274; Gallic acid tech.; NCGC00091125-03; Kyselina 3,4,5-trihydroxybenzoova [Czech]; Gallic acid, 97.5-102.5% (titration); gallicacid; 3,4,5-Trihydroxybenzoic acid, anhydrous; NSC674319; TR-020762; 3,4,5-tris(oxidanyl)benzoate; MCULE-1552954312; Gallic acid polymer; Pharmakon1600-00210369; BSPBio_001668; Tox21_111089; HMS1923K07; CCRIS 5523; BDBM50085536; NSC-674319; ST2404570; BB_SC-2795; AC-1206; 3,4,5-trihydroxy-Benzoic acid; Gallic Acid Hydrate; AC1L1934; RTR-020762; GALOP; Q-201146; SR-05000001537-1; DSSTox_CID_650; 3,4,5-Trihydroxybenzoic acid monohydrate, ACS, 98.0% min. 100g; 3,4,5-Trihydroxybenzoic acid ion; GALLICACID; s4603; CHEMBL288114; Gallic acid, tech.; NSC20103; 3,4,5-Trihydroxybenzoic acid; NSC755825; G0011; AB1002218; Gallic Acid, F; MolPort-000-881-260; NSC 674319; SPBio_000617; LNTHITQWFMADLM-UHFFFAOYSA-M; Spectrum_000342; PS-8710; SC-46383; FT-0626592; BBL009937; MFCD00002510; SpecPlus_000307; 3,4,5-trihydroxy-Benzoate; SCHEMBL15012; DSSTox_GSID_20650; ST083487; SR-05000001537; 3,5-Trihydroxybenzoic acid; 3,4,5-Trihydroxybenzoate, X; Tox21_111089_1; Gallic acid (Monohydrate or Anhydrous) (3,4,5-Trih; 3,4,5-Trihydroxybenzoic acid;; Z966690556; 3,4,5-Trihydroxybenzoate; SDCCGMLS-0066503.P001; Pyrogallol-5-carboxylic acid; BC200279; Spectrum2_000399; HY-N0523; HSDB 2117; AC1Q732Y; DTXSID0020650; 5-Trihydroxybenzoic acid; AKOS000119625; NSC 20103; Gallic acid, tech; 138-57-8; NSC-20103; AIDS-001349; gallate; CPD-183; Spectrum3_000254; KBio2_000822; Gallic acid monohydrate; AIDS-059239; KBio3_001168; Gallic acid, tech.; NSC20103; 3,4,5-Trihydroxybenzoic acid; InChI=1/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12; C01424; CHEBI:30778; EINECS 205-749-9; CHEBI:16918; NCGC00091125-01; c0006; J3.617.291F; SPECTRUM210369; Benzoic acid, 3,4,5-trihydroxy-; DivK1c_006403; NSC 674319; SPBio_000617; LNTHITQWFMADLM-UHFFFAOYSA-M; Spectrum_000342; Spectrum5_000108; NCGC00091125-02; BRN 2050274; Oprea1_087792; NCGC00091125-03; 3-10-00-02070 (Beilstein Handbook Reference); SpecPlus_000307; Kyselina 3,4,5-trihydroxybenzoova [Czech]; KBioGR_002008; AI3-16412; NSC674319; pyrogallol-5-carboxylate; 3,4,5-tris(oxidanyl)benzoate; AIDS001349; KBio2_003390; Gallic acid polymer; 1886-EP2374526A1; ZB000350; Gallic acid; BSPBio_001668; KBio2_005958; AIDS059239; CCRIS 5523; 3,4,5-Trihydroxybenzoate; SDCCGMLS-0066503.P001; Pyrogallol-5-carboxylic acid; A808977; 27645_RIEDEL; KBio1_001347; 398225_SIAL; Kyselina gallova [Czech]; WLN: QVR CQ DQ EQ; Spectrum2_000399; HSDB 2117; G7384_SIGMA; KBioSS_000822; GALOP; AC1NEVA5; SBB008781; 3,4,5-Trihydroxybenzoic acid monohydrate, ACS, 98.0% min. 100g; NSC 20103; 3,4,5-Trihydroxybenzoic acid ion; 149-91-7; 3,4,5-trihydroxybenzoic acid; Galllic acid | C7H6O5 | 170.12 | C1=C(C=C(C(=C1O)O)O)C(=O)O |
| TCMBANKIN058071 | gallic acid 3- o -(6-galloylglucoside) | Gallic acid-3-O-(6'-O-galloyl)glucoside; gallic acid-3-O-(6'-O-galloyl)-glucoside; 3,4-dihydroxy-5-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[oxo-(3,4,5-trihydroxyphenyl)methoxy]methyl]-2-tetrahydropyranyl]oxy]benzoic acid; 3,4-dihydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[(3,4,5-trihydroxybenzoyl)oxymethyl]tetrahydropyran-2-yl]oxy-benzoic acid; 3,4-dihydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[(3,4,5-trihydroxybenzoyl)oxymethyl]oxan-2-yl]oxybenzoic acid; gallicacid-3-o-(6'-o-galloyl)glucoside; 3,4-dihydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[(3,4,5-trihydroxyphenyl)carbonyloxymethyl]oxan-2-yl]oxy-benzoic acid; gallic acid-3-o-(6'-o-galloyl)-glucoside | C20H20O14 | 484.36 | C1=C(C=C(C(=C1O)O)O)C(=O)OCC2C(C(C(C(O2)OC3=CC(=CC(=C3O)O)C(=O)O)O)O)O |
| TCMBANKIN058192 | isoliquiritigenin | HCC; KBio2_000625; SPBio_000949; Spectrum2_000875; 961-29-5; 2-PROPEN-1-ONE, 1-(2,4-DIHYDROXYPHENYL)-3-(4-HYDROXYPHENYL)-; SPECTRUM1504200; Chalcone, 2',4,4'-trihydroxy-; CHEMBL1395334; KBio3_002631; NCGC00015556-01; SDCCGMLS-0066751.P001; ST5309279; (2E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; KBio2_003193; InChI=1/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3; (E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; CMLD3_000056; BSPBio_003411; C08650; CCRIS 7676; 2',4,4'-Trihydroxychalcone; Lopac0_000681; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; I159_SIGMA; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; Lopac-I-3766; CPD-3041; KBio1_001802; MEGxp0_001326; ZINC3869607; BRN 1914295; MLS000438943; SMR000112969; Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxyphenyl)-; (2E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; ACon1_000047; GU 17; KBioGR_002232; DivK1c_006858; KBio2_005761; 1-08-00-00707 (Beilstein Handbook Reference); 4,2′,4′-Trihydroxychalcone; (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; NCGC00090504-01; (Z)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; EU-0100681; Spectrum3_001656; AC1O7G44; 4,2',4'-Trihydroxychalcone; EINECS 237-316-5; I3766_SIGMA; AIDS035379; AIDS-035379; 13745-20-5; Spectrum5_000612; 2-propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (2E)-; Spectrum_000145; KBioSS_000625; Isoliquiritigenin; Spectrum4_001756; 42'4'-trihydroxychalcone; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (E)-; NCGC00090504-03; SpecPlus_000762; 2',4',4-trihydroxychalcone | C15H12O4 | 256.25 g/mol | C1=CC(=CC=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O |
| TCMBANKIN058302 | (z)-8-β-d-glucopyranosyloxycinnamicacid | C15H18O8 | C1=CC=C(C=C1)C=C(C(=O)O)OC2C(C(C(C(O2)CO)O)O)O | ||
| TCMBANKIN058375 | tryptophan | (3s)2,3-dihydro-l-tryptophan; ZINC32141959;tryptophane;WV;L-tryptophan;HSDB 4142; Tryptophan, L-(8CI); AC1Q4U80; L-Tryptophan, Vetec(TM) reagent grade, >=98%; alpha-Aminoindole-3-propionic acid; SR-01000075590-1; ZINC83315; 1-beta-3-Indolylalanine; L-(-)-Tryptophane; MolPort-044-812-611; IDI1_000457; MFCD00064340; L-2-Amino-3-indolepropionic acid; 8DUH1N11BX; STR02722; NCGC00261868-01; EU-0101183; Lopac0_001183; Tryptophan, L-; 80206-30-0; Tryptophan, European Pharmacopoeia (EP) Reference Standard; (s)-a-amino-b-indolepropionate; Tox21_201246; L-Trytophan; bmse000868; TC-066620; (S)-2-amino-3-(1H-Indol-3-yl)-propionic acid; Sedanoct; UNII-8DUH1N11BX; L-Tryptophan, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 99.0-101.0%; Propionic acid, 2-amino-3-indol-3-yl; Propionic acid, 2-amino-3-indol-3-yl-; NINDS_000457; NCI-C01729; (S)-alpha-Aminoindole-3-propionate; L-Tryptophan, Cell Culture Reagent; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; bmse001017; AB1007074; tryptophan; BB_NC-1911; 2-amino-3-indol-3-ylpropionic acid; 154635-35-5; Pacitron; L-tryptophan; 2-Amino-3-indolylpropanoate; CTK2H7431; NCGC00094437-01; 2-Amino-3-indolylpropanoic acid; TRP NH3+ COOH; ZX-AT022248; L-Tryptophan, United States Pharmacopeia (USP) Reference Standard; (S)-2-Amino-3-(3-indolyl)propionic acid; Indole-3-alanine; HMS3263N07; L-TRYPTOPHAN SIGMA GRADE; alpha-Amino-3-Indoleproprionic Acid; Tryptophan (USP/INN); L-Tryptophan (9CI); D05EJG; A7403; (L)-TRYPTOPHAN; KSC377I3D; 1H-Indole-3-alanine; Alanine, 3-indol-3-yl-; NCGC00254424-01; MCULE-8004234494; (S)-1H-Indole-3-alanine; AKOS015854052; CHEBI:16828; LP01183; Lopac-T-0254; CHEMBL54976; GTPL717; 3-Indol-3-ylalanine; F0001-2364;HSDB 4142; MT1; T0254_SIAL; tryptophan (H-3); 1-beta-3-Indolylalanine; NChemBio.2007.20-comp7; IDI1_000457; EU-0101183; Lopac0_001183; 80206-30-0; (2S)-2-amino-3-(1H-indol-3-yl)propionic acid; Sedanoct; Propionic acid, 2-amino-3-indol-3-yl-; NINDS_000457; BB_NC-1911; Pacitron; 2-Amino-3-indolylpropanoic acid; (S)-2-Amino-3-(3-indolyl)propionic acid; Indole-3-alanine; (S)-alpha-Amino-beta-(3-indolyl)-propionic acid; Tryptophan (USP/INN); L-Tryptophan (9CI); (L)-TRYPTOPHAN; Alanine, 3-indol-3-yl-; AIDS011920; CHEBI:16828; AIDS-011920; Lopac-T-0254; 3-Indol-3-ylalanine; C00078; Tryptan; TRP-01; (S)-Tryptophan 1H-Indole-3-alanine, (S)-; (S)-Tryptophan; 1H-Indole-3-alanine (VAN); AI3-18478; LS-185087; L-alpha-Aminoindole-3-propionic acid; SMR000326686; L-Alanine, 3-(1H-indol-3-yl)-; L-Trp; L-alpha-Amino-3-indolepropionic acid; Tryptophane; 1H-Indole-3-propanoic acid, alpha-amino-, (S)-; (S)-alpha-Amino-1H-indole-3-propanoic acid; alpha-Amino-3-indolepropionic acid, L-; L-Tryptofan; 1H-Indole-3-alanine, (S)-; 1beta-3-Indolylalanine; (-)-Tryptophan; MLS001056750; alpha'-Amino-3-indolepropionic acid; Indoe-3-propionic acid, alpha-amino-; LTR; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; Indole-3-propionic acid, alpha-amino-; (S)-alpha-Aminoindole-3-propionic acid; Alanine, 3-indol-3-yl; T8941_SIGMA; (S)-alpha-Amino-beta-indolepropionic acid; NSC 13119; CCRIS 617; L-Tryptophane; Tryptophane [French]; Tryptophanum [Latin]; 93659_FLUKA; D00020; Ardeytropin; DivK1c_000457; EINECS 200-795-6; EH 121; Tryptophan, L- (8CI); Triptofano [Spanish]; L-beta-3-Indolylalanine; KBio1_000457; L-(-)-tryptophan; Kalma; NCGC00015994-01; Lyphan; Tryptophan (VAN); h-Trp-oh; Tryptophan [USAN:INN]; L-Tryptophan (JP15); T4196_SIAL Pharmakon1600-01500600; triptofano; UNII-N7U7BXP2OI component QIVBCDIJIAJPQS-VIFPVBQESA-N; 2-Amino-3-(lH-indol-3-yl)-propanoic acid; DTXSID5021419; L-Ttp; Tryptophanum; AM82273; C00078; Tryptan; TRP-01; AJ-10635; L-Tryptophan, BioUltra, >=99.5% (NT); KB-53414; (S)-Tryptophan 1H-Indole-3-alanine, (S)-; (S)-Tryptophan; (S)-a-Aminoindole-3-propionic acid; 2a4m; L-Tryptophan, reagent grade, >=98% (HPLC); 1H-Indole-3-alanine (VAN); AI3-18478; trytophan; LS-185087; BIT0720; CS-W020011; L-alpha-Aminoindole-3-propionic acid; AC1L1M8F; QIVBCDIJIAJPQS-VIFPVBQESA-N; SMR000326686; D-Trp-OH; Tryptophan (L-Tryptophan); L-Alanine, 3-(1H-indol-3-yl)-; CAS-73-22-3; Tox21_501183; L-Trp; OR28930; T 0254; ST2419449; alpha-Amino-beta-(3-indolyl)-propionic acid; UNII-X9U7434L7A component QIVBCDIJIAJPQS-VIFPVBQESA-N; ZX-AFC000605; DSSTox_GSID_21419; Tryptophane; 73T223; 1H-Indole-3-propanoic acid, alpha-amino-, (S)-; (S)-alpha-Amino-1H-indole-3-propanoic acid; alpha-Amino-3-indolepropionic acid, L-; Epitope ID:136043; AX8034769; DSSTox_CID_1419; L-Tryptofan; S(-)-1-alpha-Aminoindole-3-propionic acid; 1H-Indole-3-alanine, (S)-; 1beta-3-Indolylalanine; PubChem10984; (-)-Tryptophan; BDBM21974; MLS001056750; (s)-alpha-amino-beta-indolepropionate; CCG-205257; alpha'-Amino-3-indolepropionic acid; NCGC00094437-02; Indoe-3-propionic acid, alpha-amino-; NSC757373; C-48302; (S)-a-Amino-b-indolepropionic acid; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; Indole-3-propionic acid, alpha-amino-; (S)-alpha-Aminoindole-3-propionic acid; L(-)-Tryptophan; DSSTox_RID_76152; DB-029986; SR-01000075590; BP-13286; l-b-3-Indolylalanine; Alanine, 3-indol-3-yl; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; ACT08662; DB00150; NCGC00258798-01; LS-1622; (S)-a-Amino-1H-indole-3-propanoic acid; (S)-alpha-Amino-beta-indolepropionic acid; NCGC00094437-04; BR-50074; AB00373874_05; RTC-066620; bmse000050; NSC 13119; L-Tryptophan, PharmaGrade, Ajinomoto, EP, JP, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture; alpha-amino-beta-(3-indolyl)-pr opionic acid; GM0674; CCRIS 617; L-Tryptophane; Tryptophanum [Latin]; Tryptophane [French]; L-Tryptophan, certified reference material, TraceCERT(R); Tryptophan (H-3); (S)-a-Amino-1H-indole-3-propanoate; Tox21_300359; trp; AK-50074; Alti-Tryptophan; ANW-36308; Ardeytropin; D00020; DivK1c_000457; L-Tryptophan (JP17); (S)-(-)-Tryptopha n; NCGC00094437-03; L-Trp-OH; EINECS 200-795-6; (S)-2-Amino-3-(3-indolyl)propionic acid; L-; EH 121; EC 200-795-6; Optimax; L-Trytophane; HMS501G19; Tryptophan, L- (8CI); NSC-757373; M02943; (S)-(-)-Tryptophan; HTS001390; RP26086; Triptofano [Spanish]; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; L-beta-3-Indolylalanine; A-Amino-3-indolepropionic acid; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; MolPort-001-794-499; KBio1_000457; BG00603884; 73-22-3; Kalma; NCGC00015994-01; AN-8742; 3-(1H-indol-3-yl)-L-Alanine; FT-0627592; Lyphan; Tryptophan (VAN); trofan; L-Tryptophan premix; L-Tryptophan, Vetec(TM), 98.5%; AC-17050; L-alpha-amino-3-indolepropionic acid; h-Trp-oh; 1qaw; SCHEMBL7328; Tryptophan [USAN:INN]; L-(-)-Tryptophan; L-Tryptophan (JP15); phosphatidylserine; (S)-alpha-Amino-1H-indole-3-propanoate; l-a-Aminoindole-3-propionic acid; D-2-Amino-3-indolepropionic acid; Z1245635763; (S)-a-Aminoindole-3-propionate; tryptacin | C11H12N2O2;C3H8NO6P | 204.22 g/mol;185.07g/mol | C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)N |
| TCMBANKIN058586 | Prolinum | (-)-Proline (S)-2-Carboxypyrrolidine; 18875-45-1; (2S)-2-pyrrolidinecarboxylic acid; P5607_SIGMA; L-Proline-15N; AIDS018625; 4305-67-3; L-Proline, labeled with carbon-14; L-Proline (JAN); L-(-)-Proline; CHEBI:17203; 37159-97-0; Carboxypyrrolidine; P0380_SIAL; (-)-(S)-Proline; Proline (USP); D00035; NCGC00014017; W331902_ALDRICH; (2S)-pyrrolidine-2-carboxylic acid; (S)-pyrrolidine-2-carboxylic acid; L-Prolin; NSC-97923; P8865_SIAL; nchembio816-comp9; AIDS-018625; L-(2,3-3H)Proline; C00148; 4607-28-7; 81710_FLUKA; (2S)-proline; 608998_ALDRICH; 81709_FLUKA; proline | C5H9NO2 | 115.13 g/mol | C1CC(NC1)C(=O)O |
| TCMBANKIN058795 | (-)-phaseollidin | CHEBI:17556; AKOS032948450; CHEMBL508534; AC1Q70TS; 4CN-1496; (?)-phaseollidin; ZINC895662; Phaseollidin; BDBM50311583; DTXSID50191270; AC1L3OI5; SCHEMBL1545850; Phaseolidin; LMPK12070011; MolPort-023-298-969; 37831-70-2; BG01036204; 6H-Benzofuro(3,2-c)(1)benzopyran-3,9-diol, 6a,11a-dihydro-10-(3-methyl-2-butenyl)-, (6aR,11aR)-; Phaseollidin; (6aR,11aR)-10-(3-methylbut-2-enyl)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol; (6aR,11aR)-10-(3-methylbut-2-en-1-yl)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol; 6h-benzofuro(3,2-c)(1)benzopyran-3,9-diol, 6a,11a-dihydro-10-(3-methyl-2-butenyl)-,(6ar-cis)-; (-)-Phaseollidin; 6H-Benzofuro(3,2-c)(1)benzopyran-3,9-diol, 6a,11a-dihydro-10-(3-methyl-2-butenyl)-, (6aR-cis)-; D0A9CZ; 6H-Benzofuro[3,2-c][1]benzopyran-3,9-diol,6a,11a-dihydro-10-(3-methyl-2-buten-1-yl)-, (6aR,11aR)-; W2071; C05230; 6H-Benzofuro(3,2-c)(1)benzopyran-3,9-diol, 6a,11a-dihydro-10-(3-methyl-2-butenyl)-, (6aR-cis)-; (-)-Phaseollidin; (6aR,11aR)-10-(3-methylbut-2-enyl)-6a,11a-dihydro-6H-benzofurano[3,2-c]chromene-3,9-diol; CHEBI:17556; 37831-70-2; (6aR,11aR)-10-(3-methylbut-2-enyl)-6a,11a-dihydro-6H-[1]benzoxolo[3,2-c]chromene-3,9-diol; 6H-Benzofuro(3,2-c)(1)benzopyran-3,9-diol, 6a,11a-dihydro-10-(3-methyl-2-butenyl)-, (6aR,11aR)-; phaseollidin; C05230; (6aR,11aR)-10-(3-methylbut-2-en-1-yl)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol | C20H20O4 | 324.4 g/mol | CC(=CCC1=C(C=CC2=C1OC3C2COC4=C3C=CC(=C4)O)O)C |
| TCMBANKIN058804 | 8-Isopentenyl-kaempferol | De-O-methylanhydroicaritin; Noranhydroicaritin; CHEMBL192159; MolPort-039-063-533; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)chromone; LMPK12111981; 28610-31-3; desmethylicaritin; AC1NSX3I; AKOS025288161; 8-c-prenylkaempferol; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one; 4CN-2888; 8-isopentenyl-kaempferol; BG01643044; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)-4-chromenone; 8-Prenylkaempferol; Desmethyl Icaritin; FT-0666133; DTXSID70415743; 0V5XK67Y0S; UNII-0V5XK67Y0S; 4'-Desmethylicaritin; SCHEMBL4223551; 3,4',5,7-Tetrahydroxy-8-(3-methyl-2-butenyl)flavone; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8-(3-methyl-2-buten-1-yl)-; Noranhydroicartin; W-202198; ZINC14762765;desmethylicaritin | C20H18O6 | 354.35 | CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=CC=C(C=C3)O)O)C |
| TCMBANKIN058880 | dammarenediol II | dammar-24-ene-3β,20-diol i;dammarane type;ginsenoside;74749-74-9; UNII-3K198YD54P; LS-71251; (3S,5R,8R,9R,10R,14R,17S)-17-(2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 3K198YD54P; Ginsenosides; AC1MJ5EP | C30H52O2 | 444.73 | CC(=CCCC(C)(C1CCC2(C1CCC3C2(CCC4C3(CCC(C4(C)C)O)C)C)C)O)C |
| TCMBANKIN059357 | ganodermenonol | (5R,10S,13R,14R,17R)-17-[(E,2R)-7-hydroxy-6-methylhept-5-en-2-yl]-4,4,10,13,14-pentamethyl-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one;(5R,10S,13R,14R,17R)-17-[(E,1R)-6-hydroxy-1,5-dimethylhex-4-enyl]-4,4,10,13,14-pentamethyl-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one; (5R,10S,13R,14R,17R)-17-[(E,2R)-7-hydroxy-6-methyl-hept-5-en-2-yl]-4,4,10,13,14-pentamethyl-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one; | C30H46O2 | 438.68 | CC(CCC=C(C)CO)C1CCC2(C1(CC=C3C2=CCC4C3(CCC(=O)C4(C)C)C)C)C |
| TCMBANKIN059692 | PQN | C31H46O2 | 450.7 g/mol | CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCCC(C)CCCC(C)CCCC(C)C | |
| TCMBANKIN059711 | beta carotene | C40H56 | 536.87 | CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CCCC2(C)C)C)C)C | |
| TCMBANKIN059715 | vitamin a | C20H30O | 286.5 g/mol | CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCO)C)C | |
| TCMBANKIN059947 | vitamin b1 | C63H88CoN14O14P | 1356.4 g/mol | CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)(O)OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=N6)C(=C7C(C(C(=N7)C=C8C(C(C(=N8)C(=C4[N-]5)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[C-]#N.[Co+2] | |
| TCMBANKIN059948 | Vitamin- G | C17H20N4O6 | 376.36 | CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(CO)O)O)O | |
| TCMBANKIN060063 | gibberellin a3 | C19H22O6 | 346.4 g/mol | CC12C(C=CC3(C1C(C45C3CCC(C4)(C(=C)C5)O)C(=O)O)OC2=O)O | |
| TCMBANKIN060158 | Chaohuoside A | 979.04 | CC1C(C(C(C(O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)OC4C(C(C(C(O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)O)OC6C(C(C(C(O6)COC(=O)C)OC(=O)C)O)O)OC(=O)C | ||
| TCMBANKIN060265 | isorhamnetin-3-o-rutinoside | C28H32O16 | 624.5 g/mol | CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)OC)O)O)O)O)O)O | |
| TCMBANKIN060267 | quercetin-3,7-rutinosogalactoside | C33H40O21 | 772.7 g/mol | CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)OC5C(C(C(C(O5)CO)O)O)O)C6=CC(=C(C=C6)O)O)O)O)O)O)O)O | |
| TCMBANKIN060475 | Pennogenin | C27H42O4 | 430.6 g/mol | CC1CCC2(C(C3(C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)O)C)C)O)C)OC1 | |
| TCMBANKIN060769 | phosphatidylserine | C13H24NO10P | 385.3 g/mol | CCCC(=O)OC(COC(=O)CC)COP(=O)(O)OCC(C(=O)O)N | |
| TCMBANKIN061083 | 5-pentadecylresorcinol | C21H36O2 | 320.5 g/mol | CCCCCCCCCCCCCCCC1=CC(=CC(=C1)O)O | |
| TCMBANKIN061305 | penniclavine | C16H18N2O2 | 270.33 g/mol | CN1CC(C=C2C1CC3=CNC4=CC=CC2=C34)(CO)O | |
| TCMBANKIN061680 | Oxonuciferine | oxonuciferine; Oxonuciferine; 1,2-Dimethoxy-7H-dibenzo[de,g]quinolin-7-one; (+)-ushinsunine-beta-N-oxide; 15444-20-9; AKOS028110808; 15,16-DIMETHOXY-10-AZATETRACYCLO[7.7.1.0(2),?.0(1)(3),(1)?]HEPTADECA-1(16),2,4,6,9,11,13(17),14-OCTAEN-8-ONE; lysicamine; NSC 628003; DPBMWJXWUINLQT-UHFFFAOYSA-N; DTXSID00165628; UNII-6L30DD6R7O; AIDS008762; BRN 1486372; 7H-Dibenzo[de,g]quinolin-7-one, 1,2-dimethoxy-; 5-21-13-00382 (Beilstein Handbook Reference); 1,2-Dimethoxy-7H-dibenzo(de,g)quinolin-7-one; Noraporphin-7-one, 4,5,6,6a-tetradehydro-1,2-dimethoxy-; 7H-Dibenzo(de,g)quinolin-7-one, 1,2-dimethoxy-; MolPort-044-754-181; CHEBI:70650; D01RUH; AC1L3V30; NSC-628003; 6L30DD6R7O; NSC628003; 1,2-Dimethoxy-7H-dibenzo[de,g]quinolin-7-one #; BDBM50292452; LS-97036; 7H-Dibenzo(de,g)quinolin-7-one, 1,2-dimethoxy- (9CI); AIDS-008762; SCHEMBL2046474; CCRIS 3813; CHEMBL510090; Lysicamine | C18H13NO3 | 291.3 g/mol | COC1=C(C2=C3C(=C1)C=CN=C3C(=O)C4=CC=CC=C42)OC |
| TCMBANKIN061705 | (3r)-vestitol | (-)-Vestitone; (3R)-vestitone; 2,3-Dihydro-7-hydroxy-3-(2-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; (3R)-7-hydroxy-3-(2-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one; DTXSID60331403; SCHEMBL213646; AC1L973Q; 158112-50-6; CHEBI:16786; (3R)-7-hydroxy-3-(2-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; 7,2'-Dihydroxy-4'-methoxyisoflavanone; R-Vestitone; vestitone; C00786; (3R)-vestitol | C16H14O5 | 286.28 g/mol | COC1=CC(=C(C=C1)C2COC3=C(C2=O)C=CC(=C3)O)O |
| TCMBANKIN061736 | sakuranetin | 4',5-Dihydroxy-7-methoxyflavanone; AC1LGHGY; SCHEMBL14410473; ZINC338283; ZB010901; AJ-19902; (2R)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one | C16H14O5 | 286.28 g/mol | COC1=CC(=C2C(=O)CC(OC2=C1)C3=CC=C(C=C3)O)O |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab